Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
As two of the most-watched and fastest-growing big pharma companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) already have upwardly mobile stock prices.
And now, there's yet another piece of news that could presage even more growth over the long term. Let's explore this new development.
Novo Nordisk's blockbuster drug Ozempic is widely known for being effective at controlling type 2 diabetes. Novo also makes Wegovy for treating obesity, which is the same molecule (called semaglutide) as Ozempic. Likewise, Eli Lilly's drugs Mounjaro and Zepbound are the same molecule (tirzepatide), and they are indicated for the same two conditions.
Source Fool.com
